Anders Johnsson

Scandinavian ChemoTech AB

Anders Johnsson is the Business Unit Director at Scandinavian ChemoTech in Lund, Sweden. Mr Johnsson was instrumental in the development of the early electroporation devices and also pioneered the introduction of the first generation of electrochemotherapy to the clinics in Scandinavia. Today he is working with the second generation of electrochemotherapy, called Dynamic-ElectroEnhanced Chemotherapy which is targeted for both human and veterinary use.

dont miss

Dynamic-ElectroEnhanced Chemotherapy brings relief to palliative patients with a large tumour burden

Why larger tumours (exceeding 3 cm in diameter and 1.5 cm in depth) could not previously be treated with electrochemotherapy. Introducing a new protocol called Dynamic-ElectroEnhanced Chemotherapy and presenting its clinical data.


  • Prof Ingunn Holen: Speaking at the Oncology Convention

    Prof Ingunn Holen
    Department of Oncology and Metabolism, University of Sheffield, UK

    Tumour cell dormancy and breast cancer relapse

  • Professor Jayant Vaidya: Speaking at the Oncology Convention

    Professor Jayant Vaidya
    University College London

    Targeted intraoperative radiotherapy (TARGIT-IORT) for breast cancer

  • Dr. Catherine Zollman: Speaking at the Oncology Convention

    Dr. Catherine Zollman
    Penny Brohn UK

    Integrative oncology: supporting whole person resilience and improving cancer outcomes

  • Neil Oakley: Speaking at the Oncology Convention

    Neil Oakley
    Sheffield Teaching Hospitals NHS Trust

    Robotic Radical Prostatectomy for Prostate cancer aiming for Trifecta 2020

  • Chris Carrigan: Speaking at the Oncology Convention

    Chris Carrigan
    Bowel Cancer Intelligence UK

    Patient Engagement in the uses of Patient Data